387 results match your criteria: "centre de biologie pathologie[Affiliation]"

Alpha1-antitrypsin deficiency in Greece: Focus on rare variants.

Pulmonology

January 2024

2nd Pulmonary Medicine Department, Medical School, General University Hospital "Attikon", National and Kapodistrian University of Athens, Greece 1 Rimini Street, Haidari 12462, Greece.

Purpose: AAntitrypsin deficiency (AATD) pathogenic mutations are expanding beyond the PI*Z and PI*S to a multitude of rare variants.

Aim: to investigate genotype and clinical profile of Greeks with AATD.

Methods: Symptomatic adult-patients with early-emphysema defined by fixed airway obstruction and computerized-tomography scan and lower than normal serum AAT levels were enrolled from reference centers all over Greece.

View Article and Find Full Text PDF

A significant number of individuals with a rare disorder such as Usher syndrome (USH) and (non-)syndromic autosomal recessive retinitis pigmentosa (arRP) remain genetically unexplained. Therefore, we assessed subjects suspected of -associated disease and no or mono-allelic variants using whole genome sequencing (WGS) followed by an improved pipeline for variant interpretation to provide a conclusive diagnosis. One hundred subjects were screened using WGS to identify causative variants in or other USH/arRP-associated genes.

View Article and Find Full Text PDF

Acute Microbleeds and Microinfarcts Within the Perihematomal Area After Intracerebral Hemorrhage.

Stroke

March 2023

Univ. Lille, Inserm, CHU Lille, U1172 - LilNCog - Lille Neuroscience & Cognition, F-59000 Lille, France (L.P., A.R., V.D., C.C., V.B.).

Background: To further our understanding of the pathophysiology of spontaneous intracerebral hemorrhage (ICH) and related injury, we provided a postmortem neuropathological examination of acute microvascular lesions (microbleeds and microinfarcts) within the perihematomal area.

Methods: We included all consecutive cases (2005-2019) from the Lille University Hospital brain bank of ICH patients who died within the first month. Paraffin-embedded tissue sections from the perihematomal area were processed for several stainings and immunolabelings to investigate the presence of acute microbleeds and microinfarcts in the perihematomal area and to characterize surrounding neuronal and systemic inflammatory reaction (macrophages and neutrophils).

View Article and Find Full Text PDF
Article Synopsis
  • Recreational use of nitrous oxide (NO) can lead to serious neurological and psychological disorders, prompting the need for reliable biological markers to diagnose abuse.
  • The study analyzed data from 52 chronic NO abusers to evaluate the effectiveness of total vitamin B12, homocysteine, and methylmalonic acid (MMA) in correlating with NO consumption and clinical outcomes.
  • While no specific marker was found for the level of NO consumption, elevated homocysteine levels indicated recent use, and MMA showed a stronger correlation with the severity of clinical symptoms.
View Article and Find Full Text PDF

Total alkaline phosphatase levels by gestational age in a large sample of pregnant women.

Placenta

February 2023

Univ. Lille, CHU Lille, Hôpital Jeanne de Flandre, Pôle Femme Mère Nouveau-né, F-59000, Lille, France; Univ. Lille, ULR 2694, METRICS, Evaluation des Technologies de Santé et des Pratiques Médicales, F-59000, Lille, France; Maternité de Beaumont, Centre Hospitalier, F-59100, Roubaix, France.

Introduction: Total alkaline phosphatase (tALP) levels rise physiologically in maternal serum during pregnancy, and excessively so in certain conditions. However, current reference values are dated, nonlinear, and based on small samples. Factors related to variation in tALP remain unexplained.

View Article and Find Full Text PDF

Evolution of antibiotic susceptibility profiles of staphylococci from osteoarticular infections: A 10-year retrospective study.

Orthop Traumatol Surg Res

December 2023

Centre de Biologie-Pathologie, Institute of Microbiology, Lille University Hospital, Rue du Pr. Jules Leclercq, 59037 Lille, France.

Background: Knowledge of the antibiotic susceptibility profiles of the bacteria responsible for osteoarticular infections is crucial for choosing the appropriate empirical antibiotic regimen. Wide use of broad spectrum antibiotics in these infections may have lead to selection of resistant bacteria. The aim of our study was to answer to these questions: (1) Did the bacterial pathogens isolated from osteoarticular infections (OAIs) and their antibiotic susceptibility profile change over the 10-year period in our University Hospital, particularly for Staphylococcus aureus and Coagulase negative staphylococci? (2) Are the antibiotics used for post-operative antibiotic therapy still effective against staphylococci involved in OAIs? (3) Are the antibiotics used for documented therapy still effective against staphylococci involved in OAIs?

Hypothesis: We hypothetise that bacterial epidemiology and antibiotic resistance rates have changed little thanks to a reasoned prescription of antibiotics in our Center.

View Article and Find Full Text PDF

[Discordant Down syndrome risk calculation with low maternal serum markers: About five cases of digynic triploidies].

Gynecol Obstet Fertil Senol

March 2023

Laboratoire de dépistage périnatal, centre de biologie pathologie génétique, CHU, CS 70002, 59037 Lille cedex, France; ABA: Association des Biologistes Agréés pour le dépistage de la trisomie 21 fœtale, France. Electronic address:

Objective: We compare the risk of Down syndrome among five patients carrying a foetus with digynic triploidy and suggest a course of action for these particular serological profiles.

Methods: The concentrations of the different markers used are transformed into multiples of the median by using each of the three software types present on the French market which then determine the risk of Down syndrome.

Results: For comparable biochemical and ultrasound profiles, the risk of Down syndrome turns out to be vastly different depending on the type of software employed.

View Article and Find Full Text PDF

Trial of Deferiprone in Parkinson's Disease.

N Engl J Med

December 2022

From the Departments of Medical Pharmacology (D. Devos, A.-S.R., R.B., J.-C.D.), Neuroradiology (R.V., G.K., R.L., J.-P.P.), and Neurology (L.D., C.M.), University of Lille, Lille Neuroscience and Cognition, Team DVCD, INSERM Unité Mixte de Recherche Scientifique (UMRS) 1172, Centre Hospitalier Universitaire (CHU) de Lille, Expert Center of Parkinson's Disease, Lille Center of Excellence for Neurodegenerative Disorders (LiCEND) Network of Centers of Excellence in Neurodegeneration (CoEN) Center, NS-Park/FCRIN network, the Department of Biostatistics, University of Lille, CHU de Lille (J.L., A.D.), CHU de Lille, Direction de la Recherche et de l'Innovation (P.G.D., T.O., C.P., C.L.) and Vigilance des Essais Cliniques and Service de Pharmacologie (T.O., C.P., C.L.), CHU de Lille, Laboratoire de Biochimie-Hormonologie, Centre de Biologie Pathologie (P.P.), the University of Lille, CHU de Lille, Institut Pasteur de Lille, ULR4483-Impact de l'Environnement Chimique sur la Santé Humaine (G.G., O.S., J.C.), and the University of Lille, INSERM, CHU de Lille, Unité 1172-Degenerative and Vascular Cognitive Disorders (D. Deplanque), Lille, Clinical Investigation Center 1436, Departments of Neurosciences and Clinical Pharmacology, NS-Park/FCRIN network and NeuroToul CoEN Center, University Hospital of Toulouse, INSERM, University of Toulouse 3, Toulouse (O.R., F.O.-M.), Sorbonne Université, Assistance Publique-Hôpitaux de Paris (AP-HP), INSERM, Centre National de la Recherche Scientifique (CNRS), Paris Brain Institute-Institut du Cerveau et de la Moelle Épinière (ICM), Department of Neurology, Centre d'Investigation Clinique Neurosciences, Hôpital Pitié-Salpêtrière (J.-C.C.), Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, and AP-HP, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine (M.-O.H.), Centre pour l'Acquisition et le Traitement des Images, US52-UAR2031, Commissariat à l'Énergie Atomique et aux Énergies Alternatives (CEA), ICM, Sorbonne Université, CNRS, INSERM, AP-HP (M.-O.H., J.-F.M., M.C.), Paris Brain Institute-ICM, Center for Neuroimaging Research, Sorbonne Université, INSERM Unité 1127, CNRS 7225, Department of Neuroradiology, Hôpital Pitié-Salpêtrière, AP-HP (S.L.), and ICM, CNRS UMR 7725, INSERM, Unité 1127, Sorbonne Université (J.-F.M., M.C.), Paris, the Department of Neurology, NS-Park/FCRIN network, Strasbourg University Hospital, Fédération de Médecine Translationnelle de Strasbourg, Université de Strasbourg, Strasbourg (C.T.), Assistance Publique-Hôpitaux de Marseille, Department of Neurology and Movement Disorders, Timone University Hospital and Institut de Neurosciences de la Timone, Unité Mixte de Recherche (UMR) 7289, CNRS-Aix Marseille Université, Marseille (A.E.), University of Lyon, CNRS, UMR 5229, Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de Neurologie, Centre Expert Parkinson NS-Park/FCRIN network, Bron (S.T.), Université Clermont Auvergne, EA7280, Clermont-Ferrand University Hospital, Neurology Department, Clermont-Ferrand (A.-R.M.), CHU de Bordeaux, Service de Neurologie des Maladies Neurodégénératives, Institut des Maladies Neurodégénératives (IMN) Clinique, University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux (W.G.M.), and Université Paris-Saclay, CEA, CNRS, NeuroSpin, Baobab, Gif-sur-Yvette (J.-F.M., M.C.) - all in France; the Department of Neurology, Medical University Innsbruck, Innsbruck, Austria (W.P., K.S.); Parkinson's Disease and Movement Disorders Unit, Hospital Clínic de Barcelona-Institut d'Investigacions Biomèdiques August Pi I Sunyer-Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED)-European Reference Network for Rare Neurological Diseases, Maria de Maeztu Excellence Center-Institut de Neurociències, Universitat de Barcelona (Y.C.), and the Movement Disorders Unit, Neurology Department, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Department of Medicine, Sant Pau Biomedical Research Institute, and CIBERNED (J.K.), Barcelona, and the Movement Disorders Unit, Hospital Germans Trias i Pujol, Badalona (D.V.) - all in Spain; Clinical Ageing Research Unit, Newcastle University, Newcastle upon Tyne (N.P.), Addenbrooke's Hospital (P.W.) and the ALBORADA Drug Discovery Institute, University of Cambridge, Cambridge Biomedical Campus (J.A.D.), Cambridge, and Parkinson's UK, London (D.T.D.) - all in the United Kingdom; the Department of Neurology and Center of Clinical Neuroscience, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic (E.R., P.D.); Radboud University Medical Center, Donders Institute for Brain, Cognition, and Behavior, Department of Neurology, Nijmegen (B.P., B.R.B.), and Amsterdam UMC location University of Amsterdam, Department of Neurology, and Amsterdam Neuroscience, Neurodegeneration, Amsterdam (R.M.A.B.) - all in the Netherlands; the Department of Neurology, Christian Albrechts University Kiel, Kiel (D.B., W.M.), the Department of Neurology, University Clinic, Ulm (M.O.), the Department of Geriatric Medicine, University Duisburg-Essen, Essen (R.D.), Rostock University Medical Center, Department of Neurology, and the German Center for Neurodegenerative Diseases, Research Site Rostock, Rostock (U.W.), and University Hospital of the Saarland, Homburg (S.B.) - all in Germany; Centro de Investigação em Arquitetura, Urbanismo e Design, Faculdade de Arquitetura, Universidade de Lisboa (J.F.), and Hospital de Santa Maria (M.V.S.C.), Lisbon, the Department of Neurology, Hospital da Senhora da Oliveira, Guimarães (M.G.), Life and Health Sciences Research Institute, School of Medicine, University of Minho, Braga (M.G.), and Hopitais da Universidade de Coimbra, Department of Neurology, Coimbra (C.J.) - all in Portugal; the Department of Medicine, University of Otago, Christchurch Campus, and New Zealand Brain Research Institute - both in Christchurch, New Zealand (W.G.M.); the Department of Medical Sciences, Neurology, Uppsala University, Uppsala, Sweden (D.N.); Leslie Dan Faculty of Pharmacy, University of Toronto, ApoPharma, and Chiesi Canada - all in Toronto (C.F., M.S., F.T.); Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia (S.A., A.I.B., J.A.D.); and the Department of Biological Chemistry, Alexander Silberman Institute of Life Sciences, Hebrew University, Jerusalem, Israel (I.C.).

Background: Iron content is increased in the substantia nigra of persons with Parkinson's disease and may contribute to the pathophysiology of the disorder. Early research suggests that the iron chelator deferiprone can reduce nigrostriatal iron content in persons with Parkinson's disease, but its effects on disease progression are unclear.

Methods: We conducted a multicenter, phase 2, randomized, double-blind trial involving participants with newly diagnosed Parkinson's disease who had never received levodopa.

View Article and Find Full Text PDF

Suspicion of bacterial aspiration pneumonia (BAP) is frequent during generalized convulsive status epilepticus (GCSE). Early identification of BAP is required in order to avoid useless antibiotic therapy. In this retrospective monocentric study, we aimed to determine the incidence of aspiration syndrome and BAP in GCSE requiring mechanical ventilation (MV) and factors associated with the occurrence of BAP.

View Article and Find Full Text PDF
Article Synopsis
  • FLT3-ITDs are important markers for assessing risk in acute myeloid leukemia (AML), and a new algorithm called FiLT3r has been developed to efficiently identify and quantify these markers using high-throughput sequencing (HTS) data without the need for alignment.
  • FiLT3r focuses on specific k-mers from FLT3 exons 14 and 15, and tests showed it outperformed existing software and the gold standard method in accuracy, achieving no false positives or negatives in a study involving 185 AML patients.
  • The algorithm is resource-efficient, and its results were confirmed using public RNA-Seq data; FiLT3r is available for free
View Article and Find Full Text PDF

A PMM2-CDG caused by an A108V mutation associated with a heterozygous 70 kilobases deletion case report.

Ital J Pediatr

October 2022

UMR 8576, Univ. Lille, CNRS, UGSF - Unité de Glycobiologie Structurale Et Fonctionnelle, 59000, Lille, France.

Background: Congenital Disorders of Glycosylation (CDG) are a large group of inborn errors of metabolism with more than 140 different CDG types reported to date (1). The first characterized, PMM2-CDG, with an autosomal recessive transmission, is also the most frequent. The PMM2 gene encodes a phosphomannomutase.

View Article and Find Full Text PDF

The Changing Landscape of Invasive Fungal Infections in ICUs: A Need for Risk Stratification to Better Target Antifungal Drugs and the Threat of Resistance.

J Fungi (Basel)

September 2022

UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, CNRS, Institut de Microbiologie-Centre de Biologie Pathologie Génétique, Service de Mycologie Médicale, Inserm U1285, Université de Lille, CHU Lille, F-59000 Lille, France.

The landscape of invasive candidiasis and invasive aspergillosis has changed dramatically in intensive care units over the past two decades. Today, we are faced with new risk factors such as the emergence of resistance, but are also equipped with new therapeutic strategies and diagnostic tools which are changing epidemiological data and diagnostic algorithms. Some common points need to be addressed: (i) the best way to use microbiological tools and to integrate their results in decisional algorithms; (ii) the need to find the optimum balance between under-diagnosis and overtreatment; (iii) and the need to decipher pathophysiology.

View Article and Find Full Text PDF

Iron deficiency is a significant comorbidity of heart failure (HF), defined as the inability of the myocardium to provide sufficient blood flow. However, iron deficiency remains insufficiently detected. Iron-deficiency anemia, defined as a decrease in hemoglobin caused by iron deficiency, is a late consequence of iron deficiency, and the symptoms of iron deficiency, which are not specific, are often confused with those of HF or comorbidities.

View Article and Find Full Text PDF

The presence of numerous mast cells (MCs) mixed with tumor cells in the bone marrow (BM) is a hallmark of the diagnosis of Waldenström's macroglobulinemia (WM). MCs have been shown to support lymphoplasmacytic cell growth, but there is thus far no demonstration of the prognostic impact of BM MC density in WM. We investigated BM MC density by sensitive and specific digital quantification, allowing the analysis of a large area infiltrated by BM tumor cells.

View Article and Find Full Text PDF

A novel variant associated with an atypical moderate and late-onset LCHAD deficiency.

Mol Genet Metab Rep

June 2022

Univ. Lille, Inserm, CHU Lille, U1172-LilNCog-Lille Neuroscience & Cognition, F-59000 Lille, France.

Background: Long chain 3-hydroxyacyl-CoA dehydrogenase deficiency (LCHADD) is a rare inherited disease caused by pathogenic variants of gene. Along with signs common to fatty acid oxidation defects (FAOD), specific retina and heart alterations are observed. Because long-chain fatty acid oxidation is selectively affected, supplementations with short/medium-chain fats represent energetic sources bypassing the enzymatic blockade.

View Article and Find Full Text PDF

Previously, the in vitro growth of cancer stem cells in the form of tumor spheres from five different brain cancer cell lines was found to be methionine-dependent. As this earlier work indicated that , a folate-dependent mitochondria aldehyde dehydrogenase gene, is upregulated in glioblastoma stem cells, we invalidated this gene using CRISPR-cas 9 technique in this present work. We reported here that this invalidation was effective in U251 glioblastoma cells, and no cas9 off target site could be detected by genome sequencing of the two independent knockout targeting either exon I or exon III.

View Article and Find Full Text PDF

Acute myeloid leukemia (AML) is characterized by blocked differentiation and extensive proliferation of hematopoietic progenitors/precursors. Relapse is often observed after chemotherapy due to the presence of residual leukemic cells, which is also called minimal residual disease (MRD). Subclonal heterogeneity at diagnosis was found to be responsible for MRD after treatment.

View Article and Find Full Text PDF

Current Advances in 3D Bioprinting for Cancer Modeling and Personalized Medicine.

Int J Mol Sci

March 2022

UMR 9020-UMR-S 1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, Institut de Recherche Contre le Cancer de Lille, University Lille, CNRS, Inserm, CHU Lille, F-59000 Lille, France.

Tumor cells evolve in a complex and heterogeneous environment composed of different cell types and an extracellular matrix. Current 2D culture methods are very limited in their ability to mimic the cancer cell environment. In recent years, various 3D models of cancer cells have been developed, notably in the form of spheroids/organoids, using scaffold or cancer-on-chip devices.

View Article and Find Full Text PDF

Nitrous oxide abuse in the emergency practice, and Review of toxicity mechanisms and potential markers.

Food Chem Toxicol

April 2022

Inserm, Univ. Lille EA 7364 RADEME, CHU Lille, Centre de Biologie Pathologie Génétique, UF Métabolisme Général et Maladies Rares, F-59000, Lille, France. Electronic address:

Nitrous oxide (NO) toxicity is a concern common to several medical fields. Here, retrospective study of four NO abuses with neurological signs in the emergency practice provides a preliminary basis for a metabolic Discussion/Review. This latter highlights NO abuse as pathology of DNA/RNA/protein methylations, for instance consistent with impairments of protein arginine methyltransferases involved in myelinogenesis and myelopathy in patients.

View Article and Find Full Text PDF

[Uncertainty of measurement and result from a complex calculation: about the risk of fetal Down's syndrome by maternal serum markers].

Ann Biol Clin (Paris)

February 2022

Laboratoire de dépistage périnatal, Centre de Biologie Pathologie Génétique, CHU, Lille, France, Association ABA, Hôpital Robert-Debré, AP-HP, Paris, France.

Screening for fetal Down's syndrome has the peculiarity of combining the biochemical assay of 2 or 3 serum markers with the risk associated with maternal age. If the accuracy of measurement of each parameter is known by the biologist, the uncertainty of the ultimate risk to the patient is not. Indeed, the means of risk calculation involve numerous multi-parameter equations which are not practical for daily use.

View Article and Find Full Text PDF